BACKGROUND: Although statins have indisputably proven to reduce fatal and nonfatal events in patients with cardiovascular disease, many patients with established cardiovascular disease do not receive them. Research into the effective and efficient implementation of current guidelines on secondary prevention is therefore needed. DESIGN: A cluster randomized implementation trial was conducted between September 2006 and February 2008. METHODS: Experimental pharmacists received an intensive implementation programme, whereas control pharmacists received an educational manual only. Pharmacists in both the groups were asked to identify eligible patients and to provide general practitioners (GPs) with lists of these patients. Physicians received instructions from the pharmacists to review the patients regarding a statin indication and to start a statin when they considered this as appropriate. Main outcome measure was the percentage of identified patients who received one or more statin prescriptions at 6 months follow-up. RESULTS: Although twice as many patients were reviewed for a statin indication by a GP in the experimental group (19.7 vs. 10.8%, P = 0.023), an equally low number of patients in the experimental group and the control group received statins (5.8 vs. 5.3%, P = 0.104). CONCLUSION: The intensive implementation programme had an impact on pharmacists and GPs, but did not result in more patients receiving statins.
RCT Entities:
BACKGROUND: Although statins have indisputably proven to reduce fatal and nonfatal events in patients with cardiovascular disease, many patients with established cardiovascular disease do not receive them. Research into the effective and efficient implementation of current guidelines on secondary prevention is therefore needed. DESIGN: A cluster randomized implementation trial was conducted between September 2006 and February 2008. METHODS: Experimental pharmacists received an intensive implementation programme, whereas control pharmacists received an educational manual only. Pharmacists in both the groups were asked to identify eligible patients and to provide general practitioners (GPs) with lists of these patients. Physicians received instructions from the pharmacists to review the patients regarding a statin indication and to start a statin when they considered this as appropriate. Main outcome measure was the percentage of identified patients who received one or more statin prescriptions at 6 months follow-up. RESULTS: Although twice as many patients were reviewed for a statin indication by a GP in the experimental group (19.7 vs. 10.8%, P = 0.023), an equally low number of patients in the experimental group and the control group received statins (5.8 vs. 5.3%, P = 0.104). CONCLUSION: The intensive implementation programme had an impact on pharmacists and GPs, but did not result in more patients receiving statins.
Authors: Caroline H P A Van de Steeg-van Gompel; Michel Wensing; Peter A G M De Smet Journal: BMC Health Serv Res Date: 2011-11-16 Impact factor: 2.655
Authors: Liz Steed; Ratna Sohanpal; Adam Todd; Vichithranie W Madurasinghe; Carol Rivas; Elizabeth A Edwards; Carolyn D Summerbell; Stephanie Jc Taylor; R T Walton Journal: Cochrane Database Syst Rev Date: 2019-12-06
Authors: Heidemarie Keller; Oliver Hirsch; Petra Kaufmann-Kolle; Tanja Krones; Annette Becker; Andreas C Sönnichsen; Erika Baum; Norbert Donner-Banzhoff Journal: BMC Public Health Date: 2013-07-02 Impact factor: 3.295
Authors: Tomáš Štulc; Věra Lánská; Michaela Šnejdrlová; Michal Vrablík; Martina Prusíková; Richard Češka Journal: Arch Med Sci Date: 2016-12-29 Impact factor: 3.318